Titanium-nitride-oxide coated stents versus paclitaxel-eluting stents in acute myocardial infarction: a 12-months follow-up report from the TITAX AMI trial.
OBJECTIVE
The aim of this study was to evaluate the effectiveness of titanium-nitride-oxide (TITANOX)-coated stent and paclitaxel-eluting stent (PES) in patients presenting with acute myocardial infarction (MI).


RESULTS
A total of 425 patients presenting with acute non-ST-elevation MI or ST-elevation MI were randomly assigned to receive TITANOX-coated stent or PES. The primary end point was a composite of MI, target lesion revascularisation (TLR) or death from cardiac causes. At 12 months, there was no significant difference between patients receiving TITANOX-coated stent or PES in the rates of primary end point (10.3% vs. 12.8%, P=0.5), MI (4.2% vs. 8.1%, P=0.1), or TLR (9.3% vs. 7.1%, P=0.5), respectively. The incidence of stent thrombosis, defined according to Academic Research Consortium classification, was significantly lower in the TITANOX group compared to the PES group (0.9% vs. 4.3%, P=0.03).


CONCLUSIONS
TITANOX-coated stent and PES resulted in comparable clinical outcomes during 12 months follow-up among patients treated for acute MI.
Karjalainen
Pasi P
PP
Department of Cardiology, Satakunta Central Hospital, Pori, Finland. pasi.karjalainen@satshp.fi
Ylitalo
Antti
A
Niemelä
Matti
M
Kervinen
Kari
K
Mäkikallio
Timo
T
Pietili
Mikko
M
Sia
Jussi
J
Tuomainen
Petri
P
Nyman
Kai
K
Airaksinen
K E Juhani
KE
D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D018572:Disease-Free Survival; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D012008:Recurrence; D012307:Risk Factors; D013927:Thrombosis / Q000517:prevention & control; D014025:Titanium; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; C434243:titanium-nitride-oxide; D014025:Titanium; D017239:Paclitaxel